Well, the FDA is certainly under the gun with this whole Mylan EpiPen saga. Lots of blame to be passed around but the crux of the issue really is cost. Costs are definitely brought down when safe and effective generic medicines are approved quicker. The FDA controls that part/process folks.
To me, the more (bad) press for Mylan and the FDA - the better chance Fluticare gets approved any day now. Seriously, it is safe and effective - is it not?
(1)
(0)
Innovus Pharmaceuticals Inc. (INNV) Stock Research Links